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Abstract
Background: Atrial fibrillation (AF) is associated with increased mortality and morbidity, including risk for cerebral
macro- and microinfarctions and cognitive decline, even in the presence of adequate oral anticoagulation. AF is
strongly related to increased inflammatory activity whereby anti-inflammatory agents can reduce the risk of new or
recurrent AF. However, it is not known whether anti-inflammatory therapy can also modify the deterioration of
neurocognitive function in older patients with AF. In the present study, older patients with AF were treated with
intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg, or placebo. We examined the
relationship between neurocognitive functions and inflammatory burden.
Findings: Analysis of inflammatory markers revealed significant reductions in high sensitivity C-reactive protein
(hs-CRP), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-9, IL-13 and IL-17, and
interferon-γ (IFNγ) in the treatment group compared to placebo. Reduction in plasma concentration of IL-1RA, IL-2,
IL-9 and IL-12, and macrophage inflammatory protein-1β (MIP-1β) correlated significantly with improvement in the
neurocognitive functions memory and speed. Loss of volume in amygdala and hippocampus, as determined by
magnetic resonance imaging (MRI), was reduced in the treatment arm, statistically significant for left amygdala.
Conclusions: Anti-inflammatory therapy through intensive lipid-lowering treatment with atorvastatin 40 mg and
ezetimibe 10 mg can modify the deterioration of neurocognitive function, and the loss of volume in certain
cerebral areas in older patients with AF.
Trial registration Clinical Trials.gov: NCT00449410
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Background
Atrial fibrillation (AF) is a common arrhythmia, and
even with optimal treatment it is associated with con-
siderable morbidity and mortality. Current therapies in-
clude anticoagulation, rhythm and rate control, and in
selected cases pulmonary vein isolation and ablation.
There is increasing interest in inflammatory aspects of
AF [1,2], beneficial effects of anti-inflammatory agents
[3-6] and blocking of the renin-angiotensin-aldosterone
system (RAAS) to prevent the arrhythmia [7,8]. The
aspect of inflammation as part of the general aging
process has also been addressed recently [9,10]. Oral
anticoagulation significantly reduces the risk of throm-
boembolic complications in AF, but even with an inter-
national normalized ratio (INR) within the therapeutic
range strokes do occur. Furthermore, even in the ab-
sence of overt strokes, patients with AF have an
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increased risk of cognitive decline and development of
dementia [11-16].
AF patients have elevated plasma concentration of sev-
eral inflammatory markers, and in patients without AF a
possible relation between these markers and Alzheimer’s
disease has been suggested [17]. There is increasing evi-
dence linking inflammation to thrombosis [1,18,19]. A pos-
sible explanation for the development of dementia in AF
patients may be thrombotic microinfarctions triggered by
inflammatory processes and not necessarily microemboli.
We have recently shown that patients with AF on adequate
oral anticoagulation remain in a prothrombotic state, as in-
dicated by the presence of endogenous thrombin potential
[20]. This was reduced by intensive lipid-lowering therapy
with a combination of 40mg atorvastatin and 10mg
ezetimibe. The therapy was associated with lower levels of
a number of inflammatory parameters [20], as well as a re-
duced decline in several neurocognitive functions in associ-
ation with changes in limbic regions mediating these
functions [21]. However, it remains unclear whether the
obvious clinical benefit of change in inflammatory markers
in AF also relates to a positive effect on neurocognitive
functions. We therefore extend our previous findings and
report on the relationship between the inflammatory
changes and neuropsychological performance, as well as
structural changes of amygdala, hippocampus and white
matter lesions, which are mainly associated with the
neurocognitive decline in AF.
Patients, materials and methods
Study design
The patients, blood analyses, electrocardiograms and echo-
cardiograms in this study have been described in detail else-
where [20]. The study complied with the Declaration of
Helsinki and was approved by the medical ethics commit-
tees of the Radboud University Nijmegen Medical Centre
and the Canisius Wilhelmina Medical Centre, both in
Nijmegen, the Netherlands. Patients were included in the
study only after having given a written consent of participa-
tion.Briefly, 34 patients with AF and without indication for
lipid-lowering therapy were randomized to receive either
atorvastatin 40 mg and ezetimibe 10 mg, or double placebo
for 1 year. Baseline characteristics of the patients are given
in Table 1. Prothrombin INR and dosage of coumarin/
warfarin were similar in both groups and were unchanged
throughout the study. Blood samples were collected at
inclusion, and after 1, 3, 6, 9 and 12 months. Cytokines,
chemokines and selected growth factors were analysed
using a multiplex cytokine assay (Bio-Plex Human Cytokine
27-Plex Panel, Bio-Rad Laboratories Inc, Hercules, CA,
USA) as previously described [20]. Complement activation
products were determined in enzyme immunoassays as de-
scribed [22]. Plasminogen activator inhibitor (PAI) was
analysed in a Chromolize immunoassay (Biopool, Umeå,
Sweden). Plasmin peak height was analysed using the
Nijmegen Hemostasis Assay as described earlier [20,23].
Neurocognitive tests
All participants underwent a face-to-face clinical interview
by a neuropsychologist, followed by a comprehensive neu-
ropsychological assessment. The clinical interview ruled
out a depressive disorder. The assessment was performed
at baseline and 1year after enrolment in the study. An
overview of the tests is given in Table 2.
Neuroimaging
All participants underwent T1 weighted and fluid attenu-
ated inversion recovery at 1.5T with magnetic resonance
imaging (MRI) scanning (Siemens, Munich,Germany) as
described elsewhere [21].
Statistics
To evaluate whether changes in brain areas were associ-
ated with treatment, the 12-month value of each area was
regressed on its baseline value and a treatment indicator.
The P value associated with the treatment indicator pro-
vides a test of whether changes in area-volume are associ-
ated with treatment.
The Spearman correlation between changes in cognitive
test scores or MRI findings and changes in inflammatory
parameters was computed. Since there were 35 different
inflammatory parameters and a long range of cognitive
tests, a number of statistically significant differences just
by chance would be expected. To circumvent this poten-
tial pitfall, a single P value for all the different biomarkers
was computed for each cognitive test and each domain
[24]. The combined P values were computed using
Tippett’s combination method [25] and its distribution
under the null hypothesis of no association computed
using the permutation distribution.
Table 1 Baseline characteristics of treatment group
and placebo
Treatment (n=17) Placebo (n=17)
Gender (males: females) 13: 4 14: 3
Age (years) (SD) 74.5 (4.2) 73.5 (4.0)
Smoking (n/total) 1/17 1/17
Hypertension (n/total) 12/17 13/17
BMI (kg/m2) (SD) 25.6 (3.4) 26.8 (8.3)
Chronic AF (n/total) 11/17 9/17
Duration of AF (years)(SD) 13.5 (15.0) 14.0 (19.3)
Data as mean (SD). AF, atrial fibrillation; BMI, body mass index;n, number of
patients; SD, standard deviation.
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Results
Brain volume during treatment
Volumetric analyses revealed that both amygdala and
hippocampal volume decreased during the study period.
This was true for both the placebo arm and for patients
receiving active treatment; however, the reduction was
consistently smaller in the treatment group, although
statistically significant (P<0.02) only for the left amyg-
dala area (Table 3). Results were unaffected by adjust-
ment for total brain volume.
Combined P values for individual cognitive tests
and domains
By combining the P values obtained for each individual
Spearman correlation, it was possible to compute a com-
bined P value for each cognitive test and domain. For
the domains speed and memory, the correlation between
rate of decline and changes in inflammatory markers
was highly significant with P values of 0.02 and 0.03, re-
spectively (Table 4). For the domains language, switching
and attention, there was no correlation. Furthermore, for
the individual Stroop Color-Word Test IV and Trail
Making Test A, the P values were <0.01 and 0.02, re-
spectively. The clinical interviews excluded a depressive
disorder, and the Montgomery-Asberg Depression
Rating Scale was below seven in all participants at base-
line and at the end of the study.
Combined P values for individual inflammatory
parameters
In the same manner as for the cognitive test, we pooled
the P values for each inflammatory parameter across all
the various tests and domains. Changes in interleukin-1
receptor antagonist (IL-1RA), interleukin (IL)-2, IL-9 and
IL-12, and macrophage inflammatory protein-1β (MIP-1β)
significantly correlated with changes in cognitive function
with P values of 0.01, 0.04, 0.05, 0.04 and 0.01, respectively
(Table 5). For the other inflammatory markers, no statisti-
cally significant correlations were found.
Combined P values for changes in MRI and inflammatory
parameters
We found no statistically significant correlations be-
tween changes in white matter volume, white matter le-
sion volume or number of white matter lesions and
changes in inflammatory parameters. Similarly, no con-
sistent statistically significant correlations could be dem-
onstrated when examining inflammatory parameters and
white matter changes in individual cerebral regions, or
between inflammatory parameters, amygdala and hippo-
campus volume (data not shown).
Discussion
Even if optimally treated, AF is associated with increased
morbidity and mortality. Recent studies have also indi-
cated a higher prevalence of dementia among AF pa-
tients compared to matched controls [13,26]. Increased
plasma concentration of certain cytokines is associated
with dementia [17] and AF patients are known to have
elevated levels of several cytokines [27,28]. Previous
Table 2 Overview of clinical and neuropsychological assessment
Measure Domain
Clinical Multilevel Assessment Instrument Instrumental activities of daily living
Mini Mental State Examination Cognitive screening
Memory Rey Auditory Verbal Learning Test Verbal memory
Rey-Osterrieth Complex Figure Test Visual memory, constructive ability
WAIS-III: digit span Working memory, concentration
Language WAIS-III: vocabulary Language, verbal expression
Verbal fluency Language, executive functioning
Executive function/speed Reaction time tasks (ERT, SRT, CRT) Reaction time, interference
WAIS-III: digit symbol coding Speed of information processing
Stroop Color-Word Test I to III Speed of information processing, interference
Trail Making Test A Motor speed, visual scanning
Executive function/switching Trail Making Test B Switching, visual scanning, motor speed
Stroop Color-Word Test IV Switching, speed of information processing, interference
CRT, choice reaction time; ERT, elementary reaction time; SRT, simple reaction time; WAIS, Wechsler Adult Intelligence Scale.
Table 3 Volumes of selected brain areas at baseline and
end of study
Treatment (μl) Placebo (μl) P value
Baseline 1 year Baseline 1 year
Left amygdala 2,051 1,952 1,797 1,552 0.019
Left hippocampal 2,866 2,761 2,790 2,747 0.56
Right amygdala 2,082 1,992 1,829 1,628 0.20
Right hippocampal 2,944 2,866 2,972 2,814 0.50
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studies have shown that treatment with anti-
inflammatory effects can prevent postoperative AF
[6,29-31] and prevent recurrence after external cardio-
version [32,33], but it is not known whether such treat-
ment can also affect the negative consequences of the
arrhythmia on neurocognitive functions.
We have recently shown that intensive lipid-lowering
treatment reduces high sensitivity C-reactive protein (hs-
CRP) and a number of other peripheral markers of inflam-
mation in patients with AF [20]. Although a previous
study [34] indicated that a combination of simvastatin and
ezetimibe is no better than simvastatin alone in affecting
intima-media thickness in patients with familial hyper-
cholesterolemia, each statin and lipid-lowering treatment
must be evaluated independently. Furthermore, our group
of patients consisted of older AF patients without signifi-
cantly elevated cholesterol levels and the achieved lipid-
lowering effect was higher in our study compared to the
previous. In the JUPITER trial, use of rosuvastatin was as-
sociated with a reduction in vascular events in a primary
prophylaxis setting in patients with elevated C-reactive
protein (CRP) [35]. In the present study, we demonstrate
for the first time that there is a statistically significant cor-
relation between reduction in a series of inflammatory
markers and delayed neurocognitive decline, especially
memory and speed of information processing in older pa-
tients with AF. However, whether this correlation indicates
a causal relationship isunclear. Furthermore, from our re-
sults it is only possible to determine the combined effect
of atorvastatin and ezetimibe, and not the individual con-
tribution of each drug. The relative role of the various in-
flammatory markers is not clear, nor is the reason why
some markers correlated with neurocognitive decline and
some did not. It may be a result of the relatively low
number of participants (type II error) but as will be seen
below, other investigators have also demonstrated correl-
ation between cognitive function and some, but not all, of
the inflammatory markers measured.
An inverse relationship between plasma concentration of
IL-2 and the probability of successful cardioversion after
the administration of amiodarone has been demonstrated
[36]. In our study, changes in IL-2 correlated with the rate
of decline in cognitive function. To the best of our know-
ledge, the association between AF, neurocognitive function
and the inflammatory markers, IL-1RA, IL-9, IL-12 and
MIP-1β, has not previously been studied. In a recent study
in rats, Ribeiro demonstrated that induction of a pro-
inflammatory state by administration of metylmalonic acid
resulted in increased levels of interleukin-1β(IL-1ß) and
tumor necrosis factor-α (TNF-α), both in blood and in the
cerebral cortex of the animals, as well as a reduction in
spatial orientation [37].
We were unable to show any correlation between in-
flammatory markers and changes in white matter lesions
of the brain. Furthermore, there were no statistically sig-
nificant correlations between changes in inflammatory
mediators and changes in amygdala and hippocampus vol-
ume. However, our data indicate that in the treatment
group there was a trend towards a decrease in white mat-
ter lesions, while the placebo group showed an increase.
One possibility is that the smaller initial white matter le-
sion volume attenuated the treatment effect. Another is
that statistical power was insufficient due to the relatively
small group of participants. Furthermore, the follow-up
time may have been too short to detect differences in pro-
gress. The reason why the decline in only some domains
and cognitive tests correlated with changes in inflamma-
tory parameters is unclear. One possibility is that there are
Table 4 Combined P values for the correlation between inflammatory parameters, cognitive domains and tests
Attention 0.92 Speed 0.02 Language 0.12 Switching 0.12 Memory 0.03
SDST 0.21 Stro I 0.93 Stro IV 0.00 TMTA 0.02
TMTB 0.83 WTDR 0.08 ERT 0.47 NPOSOM 0.23
ERT, elementary reaction time; NPOSOM, abbreviation of the Dutch term for the total number of impaired neuropsychological tests; SDST, symbol digit
substitution test; Stro I,Stroop Color-Word Test I; Stro IV,Stroop Color-Word Test IV; TMTA, Trail Making Test A; TMTB, Trail Making Test B; WTDR,15 word test
delayed recall.
Table 5 P values for each inflammatory parameter, pooled across all cognitive tests
C1-inh 0.22 C3bc 0.77 C4bc 0.79 Properdin 0.56 TCC 0.93 PPH0.29 ETP 0.19
Eotaxin0.52 FGF 0.17 G-CSF 0.47 GM-CSF 0.41 IFNγ 0.19 MIP-1α 0.37 MIP-1β 0.01
IL-1β 0.18 IL-1RA 0.01 IL-2 0.04 IL-4 0.25 IL-5 0.11 IL-6 0.55 IL-7 0.69
IL-8 0.45 IL-9 0.05 IL-10 0.38 IL-12 0.01 IL-13 0.10 IL-15 0.56 IL-17 0.36
MCP-1 0.67 PAI 0.63 PDGF 0.44 RANTES 0.47 TNF-α 0.15 VEGF 0.40 IP-10 0.49
C1-inh, C1-inhibitor; ETP, endogenous thrombin potential; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; IFNγ, interferon-γ; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; IL-1β, interleukin-1β, IP-10 (also known as C-X-C
motif chemokine 10or CXCL10), interferon gamma-induced protein 10; MCP-1 (also known as CCL2), monocyte chemotactic protein-1; MIP-1α (also known as
CCL3), macrophage inflammatory protein-1α; MIP-1β (also known as CCL4), macrophage inflammatory protein-1β; PAI, plasminogen activator inhibitor; PDGF,
platelet-derived growth factor; PPH, plasmin peak height; RANTES (also known as CCL5), regulated on activation, normal T cell expressed and secreted; TCC,
terminal complement complex; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.
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different mechanisms for the decline across the various
functions, probably time-dependent, of which only some
are susceptible to the effects of anti-inflammatory therapy.
Another possible explanation could be the relatively low
number of patients in our study, with a risk for type II
statistical errors. However, the effect of powerful lipid-
lowering treatment on inflammatory and hemostatic
parameters reported previously [20], and the correlation
between such findings and changes in cognitive functions,
and certain brain volumes presented in this report, sup-
port the notion that there is a link between inflammation,
thrombosis and dementia in AF. Thus, larger, long-term
studies are warranted to confirm and extend our findings.
Conclusions
In this study, anti-inflammatory therapy through inten-
sive lipid-lowering treatment with atorvastatin 40 mg
and ezetimibe 10 mg apparently modified the deterior-
ation of neurocognitive function and the loss of volume
in certain cerebral areas in older patients with AF.
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